Table 4.
Incidence of all grade ≥3 treatment-related AEs that occurred during the study
Term | CTCAE grade | Number of patients (%) | |
---|---|---|---|
Eribulin only (n = 14) | Total (n = 14) | ||
Any TEAE | 3 | 6 (43) | 8 (57) |
4 | 1 (7.1) | 2 (14) | |
Fatigue | 3 | 3 (21) | 3 (21) |
Leucopenia | 3 | 4 (29) | 3 (21) |
4 | 0 | 1 (7.1) | |
Neutropenia | 3 | 2 (14) | 4 (29) |
4 | 1 (7.1) | 2 (14) | |
Febrile neutropenia | 3 | 1 (7.1) | 1 (7.1) |
Abdominal pain | 3 | 0 | 1 (7.1) |
TEAE, treatment-emergent adverse event.